Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche

Xiaowen Xu1,*, Wenjun Chang2,*, Jie Yuan1,*, Xue Han3,*, Xiaojie Tan2, Yibo Ding2, Yanxin Luo4, Hui Cai2, Yan Liu2, Xianhua Gao4, Qizhi Liu1, Yongwei Yu5, Yan Du2, Hao Wang1, Liye Ma6, Jianping Wang4, Kun Chen7, Yanqing Ding8, Chuangang Fu1, Guangwen Cao2

1Department of Colorectal Surgery, The 1st Affiliated Hospital, Second Military Medical University, Shanghai, China
2Department of Epidemiology, Second Military Medical University, Shanghai, China
3Department of Chronic Diseases, Center for Diseases Control and Prevention of Yangpu District, Shanghai, China
4Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
5Department of Pathology, The 1st Affiliated Hospital, Second Military Medical University, Shanghai, China
6Department of General Surgery, The 1st Affiliated Hospital, Second Military Medical University, Shanghai, China
7Department of Epidemiology and Biostatistics, Zhejiang University School of Public Health, Hangzhou, China
8Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China

*These authors have contributed equally to this work

Correspondence to:
Guangwen Cao, e-mail: gcao@smmu.edu.cn
Chuangang Fu, e-mail: fugang416@126.com

Keywords: colorectal carcinoma, periostin, fibroblast, drug-resistance, prognosis

Received: June 19, 2015 Accepted: October 30, 2015 Published: November 09, 2015

ABSTRACT

Periostin (POSTN) expression in cancer cells and circulation has been related to poor prognosis of colorectal carcinoma (CRC). However, the role of POSTN expressed in intra-tumoral stroma on CRC progression remains largely unknown. This study enrolled 1098 CRC patients who received surgical treatment in Shanghai and Guangzhou, Mainland China. In Shanghai cohort, immunohistochemistry score of stromal POSTN expression increased consecutively from adjacent mucosa, primary CRC tissues, to metastatic CRC tissues (P < 0.001), while medium- and high-stromal POSTN expression, rather than epithelial POSTN expression, independently predicted unfavorable prognoses of CRC, adjusted for covariates including TNM stage and postoperative chemotherapy in multivariate Cox models. The results in Shanghai cohort were faithfully replicated in Guangzhou cohort. Stromal POSTN expression dose-dependently predicted an unfavorable prognosis of stage III CRC patients with postoperative chemotherapy in multivariate Cox models. The results in Shanghai cohort were faithfully replicated in Guangzhou cohort. Stromal POSTN expression dose-dependently predicted an unfavorable prognosis of stage III CRC patients with postoperative chemotherapy in both cohorts. POSTN derived from colonic fibroblasts or recombinant POSTN significantly promoted proliferation, anchorage independent growth, invasion, and chemo-resistance of CRC cells; whereas these effects were counteracted via targeting to PI3K/Akt or Wnt/β-catenin signaling pathway. CRC cell RKO-derived factor(s) significantly induced POSTN production in colonic fibroblasts and autocrine POSTN promoted proliferation, migration, and anchorage independent growth of fibroblasts. Conclusively, stromal POSTN is prognostic and predictive for CRC via creating a niche to facilitate cancer progression. Targeting POSTN-induced signaling pathways may be therapeutic options for metastatic or chemoresistant CRC.
INTRODUCTION

Colorectal cancer (CRC) is one of the most common malignancies worldwide, with 1.23 million newly diagnosed cases annually [1]. Surgical resection is the primary option for CRC treatment. Approximately 20%–25% of CRC patients present with metastatic disease at diagnosis and another 20%–25% will develop metachronous metastases, resulting in an overall mortality rate of 40%–45% [2]. Tumor stage, circumferential resection margin involvement, obstruction/perforation, rupture during surgery, vascular and perineural invasion, poor differentiation, high-frequency microsatellite instability, mismatch repair deficiency, thymidylate synthase positivity, circulating tumor cells, KRAS mutation, BRAF mutation, and elevated expression of Snail or serpinA1 have been suggested to be prognostic for CRC [2–5]. Postoperative chemotherapy is the standard of care for stage III CRC patients. Some molecules or signatures expressed in CRC tissues can be predictive [6, 7]. Although these molecules are potentially prognostic and/or predictive, few of them are clinically applied. Identification of new biomarkers to improve CRC prognosis classification and individualized treatment is urgently needed.

Previously, we have demonstrated that periostin (POSTN) is the top overlapping molecule in signatures (4/5) with high concordance and repeatable prognostic values for CRC. Further immunohistochemistry (IHC) assays have demonstrated that POSTN is a key component of the CRC cell-derived gene signature with robust prognostic and predictive values [8]. POSTN, firstly identified as osteoblast-specific factor 2 in 1993, is a secretory, matricellular molecule with known functions in bone development/maturation/repair, tissue repair, mesenchymal remodeling, and epithelial-mesenchymal transition (EMT) [9]. POSTN expression in cancer cells (epithelial POSTN expression) can promote metastatic potential of CRC, via activating the PI3 kinase (PI3K)/protein kinase B (Akt) signaling pathway [10]. In CRC with liver metastasis, POSTN is significantly higher in CD133+ than in CD133− tumor cells [11]. We and others observed that POSTN was highly expressed in stromal cells in CRC tissues [8, 12]. POSTN expressed in cancer-associated fibroblasts or other stromal cells may facilitate the aggressiveness of pancreatic cancer, ovarian cancer, prostate cancer, esophageal adenocarcinoma, gastric cancer, breast cancer, and cholangiocarcinoma [13–19]. The elevated level of POSTN in sera is also associated with an unfavorable prognosis of CRC [20]. However, the effect of POSTN expression in intratumoral stromal cells (stromal POSTN expression) on the progression and prognosis of CRC remains largely unknown. The objective of this study is to clarify if stromal POSTN expression in tumor tissues is prognostic and/or predictive for CRC and elucidate the mechanisms by which stromal POSTN promoted the aggressiveness and drug-resistance of CRC. This study should be helpful for the prediction and targeted treatment of metastatic or chemoresistant CRC.

RESULTS

Expression pattern of POSTN in adjacent mucosa, primary CRC, and metastatic CRC tissues

Tissue microarrays (TMAs) containing surgically removed adjacent mucosa (n = 37), primary CRC at I–IV stages (n = 755), and metastatic CRC specimens (n = 21) from the 1st Affiliated Hospital of Second Military Medical University were immunostained using antibody against POSTN. POSTN was mainly expressed in the cytoplasm of stromal cells and epithelial CRC cells, as shown in Figure 1A. The immunostaining of POSTN was more intensive in stromal cells than in epithelial cancer cells in the specimens of 506 (67.02%) of the 755 CRC patients. IHC score of stromal POSTN expression was significantly higher in the metastatic CRC tissues than in primary CRC tissues (P < 0.001) and also significantly higher in primary CRC tissues than in the adjacent mucosa (P < 0.001), as shown in Figure 1B. According to IHC scores of stromal or epithelial POSTN expression, CRC patients were classified into 3 groups: low- (0–4), medium- (6–8), and high-score (9–12) groups. High IHC score of stromal POSTN expression was significantly associated with low differentiation grade (P < 0.001) and high TNM stage (P < 0.001) in 755 CRC patients (Table 1).

Stromal POSTN expression had higher discriminatory performances than epithelial POSTN expression in predicting postoperative prognosis of CRC

To compare the contributions of stromal POSTN and epithelial POSTN expression to postoperative prognosis of CRC, we initially included 682 stage I-III CRC patients who received curative surgery and regular follow-up in Shanghai cohort. The 5-year rates of disease-free survival (DFS) were 93.6%, 72.9%, and 42.3%; while the 5-year rates of disease-specific survival (DSS) were 96.2%, 85.4%, and 65.6%, in the groups with low-, medium-, and high-score of stromal POSTN expression, respectively (P < 0.001 for each). Patients with higher score of stromal POSTN expression had shorter DSS and DFS (Figure 2A, 2C). In terms of epithelial POSTN expression, however, the survivals were not significantly different between patients with high-score and those with medium-score (Figure 2B, 2D). Next, the prognostic values of POSTN expression were validated in Guangzhou cohort.
with 343 CRC patients who received curative surgery and regular follow-up. The associations of POSTN expression levels in stromal cells and in cancer cells with DSS observed in Shanghai cohort were faithfully replicated in Guangzhou cohort, as shown in Figure 2E, 2F.

Multivariate Cox regression analyses showed that medium-score and high-score stromal POSTN expression, rather than epithelial POSTN expression, were independent risk factors for DFS and DSS in Shanghai cohort, adjusted for the covariates including

Figure 1: Expression pattern of POSTN in formalin-fixed paraffin-embedded specimens of adjacent pathologically normal mucosa, primary tumors, and metastatic tumors of CRC patients in Shanghai cohort. A. Representative immunostainings of POSTN in adjacent mucosa tissues, primary tumors, and metastatic tumors. POSTN was expressed in the cytoplasm of epithelial cells and stromal cells. Bar, 50 μm. B. Expression pattern of POSTN protein in adjacent mucosa tissues, primary tumors, and metastatic tumors. Abbreviation and mark: CRC, colorectal carcinoma; ***, P < 0.001.
Table 1: Associations of stromal POSTN expression with demographic and clinical variables of 755 CRC patients in Shanghai cohort

| Characteristics                        | Stromal POSTN expression in tumor specimens |       |       |       | P value |
|----------------------------------------|---------------------------------------------|-------|-------|-------|---------|
|                                        | Low (n = 444)                               | Medium (n = 222) | High (n = 89) |       |         |
| Age (years), mean (SD)                 | 60.33 (12.77)                               | 58.96 (13.23) | 57.61 (11.97) |       | 0.133   |
| Sex, n (%)                             |                                             |       |       |       |         |
| Women                                  | 193 (43.5)                                  | 90 (40.5) | 37 (41.6) |       | 0.761   |
| Men                                    | 251 (56.5)                                  | 132 (59.5) | 52 (58.4) |       |         |
| Disease location, n (%)                |                                             |       |       |       |         |
| Colon                                  | 210 (47.3)                                  | 102 (45.9) | 42 (47.2) |       | 0.945   |
| Rectum                                 | 234 (52.7)                                  | 120 (54.1) | 47 (52.8) |       |         |
| Differentiation grade, n (%)           |                                             |       |       |       | <0.001  |
| Well                                   | 16 (3.6)                                    | 8 (3.6) | 1 (1.1) |       |         |
| Moderately                             | 269 (60.6)                                  | 119 (53.6) | 36 (40.4) |       |         |
| Poorly                                 | 125 (28.2)                                  | 79 (35.6) | 49 (55.1) |       |         |
| Missing                                | 34 (7.7)                                    | 16(7.2) | 3(3.4) |       |         |
| Number of lymph nodes, n (%)           |                                             |       |       |       | 0.607   |
| <12                                    | 198 (44.6)                                  | 96 (43.2) | 44 (49.4) |       |         |
| ≥12                                    | 246 (55.4)                                  | 126 (56.8) | 45 (50.6) |       |         |
| TNM stage, n (%)                       |                                             |       |       |       | <0.001  |
| I                                      | 40 (9.0)                                    | 10 (4.5) | 2 (2.2) |       |         |
| II                                     | 193 (43.5)                                  | 94 (42.3) | 24 (27.0) |       |         |
| III                                    | 190 (42.8)                                  | 87 (39.2) | 42 (47.2) |       |         |
| IV                                     | 21 (4.7)                                    | 31 (14.0) | 21 (23.6) |       |         |
| Adjuvant chemotherapy, n (%)           |                                             |       |       |       | <0.001  |
| Yes                                    | 362 (81.5)                                  | 199 (89.6) | 86 (96.6) |       |         |
| No                                     | 82 (18.5)                                   | 23 (10.4) | 3 (3.4) |       |         |
| Serum CEA                              |                                             |       |       |       |         |
| <5 ng/mL                               | 283 (63.7)                                  | 133 (59.9) | 50 (56.2) |       | 0.374   |
| ≥5 ng/mL                               | 161 (36.3)                                  | 89 (40.1) | 38 (42.7) |       |         |
| Missing                                | 0 (0)                                       | 0 (0) | 1 (1.1) |       |         |
| Serum CA19-9                            |                                             |       |       |       |         |
| <37 U/ml                                | 379 (85.4)                                  | 180 (81.1) | 68 (76.4) |       | 0.123   |
| ≥37 U/ml                               | 65 (14.6)                                   | 41 (18.5) | 20 (22.5) |       |         |
| Missing                                | 0 (0)                                       | 1 (0.5) | 1 (1.1) |       |         |

*aStudent-Newman-Keuls q test;  
bPearson Chi-Square test;  
cKruskal-Wallis test."
Figure 2: Comparison of discriminatory performances between stromal and epithelial POSTN expression in predicting postoperative prognoses of stage I–III CRC patients in both cohorts. 

A. stromal POSTN expression predicted DFS of CRC patients in Shanghai cohort. 
B. epithelial POSTN expression predicted DFS of CRC patients in Shanghai cohort. 
C. stromal POSTN expression predicted DSS of CRC patients in Shanghai cohort. 
D. epithelial POSTN expression predicted DSS of CRC patients in Shanghai cohort. 
E. stromal POSTN expression predicted DSS of CRC patients in Guangzhou cohort. 
F. epithelial POSTN expression predicted DSS of CRC patients in Guangzhou cohort. 

Abbreviations and marks: CRC, colorectal carcinoma; DFS, disease-free survival; DSS, disease-specific survival; *, $P > 0.05$; **, $P < 0.05$; ***, $P < 0.01$; ****, $P < 0.001$. 

www.impactjournals.com/oncotarget
TNM stage, tumor differentiation grade, and postoperative chemotherapy; higher stromal POSTN expression also predicted a poorer DSS in Guangzhou cohort independently, as shown in Table 2.

**Stromal POSTN expression predicted the prognosis of CRC patients who received postoperative chemotherapy**

We stratified patients into stage I-II CRC without chemotherapy, stage II CRC with postoperative chemotherapy, and stage III CRC with postoperative chemotherapy in Shanghai cohort. It was found that stromal POSTN expression had higher discriminatory performances of predicting DFS and DSS in stage III CRC patients with postoperative chemotherapy than in stage I-II patients without chemotherapy and in stage II patients with postoperative chemotherapy. The result of DSS was consistently replicated in Guangzhou cohort. The results are shown in Figure 3.

**POSTN promoted proliferation, anchorage independent growth, and invasion of CRC cells**

We constructed a recombinant lentiviral vector containing a full-length of human POSTN cDNA. After being amplified in 293T cells, the resulting recombinant lentiviruses were employed to infect CCD-18Co, a colon

| Table 2: Contribution of stromal POSTN expression, epithelial POSTN expression, and demographic and clinicopathological covariates to postoperative survivals of CRC patients in multivariate Cox hazard proportion models |

| Shanghai Cohort | Guangzhou Cohort |
|-----------------|------------------|
| **DFS**         | **DSS**          | **DSS**         |
| HR (95% CI)     | **P value**      | HR (95% CI)     | **P value**      | HR (95% CI)     | **P value**      |
| Stromal POSTN score |                   |                   |                   |                   |                   |
| Low             | 1.00             | 1.00             | 1.00             |
| Medium          | 5.14 (3.21–8.23) | <0.001           | 4.14 (2.12–8.11) | <0.001           | 2.71 (1.43–5.14) | 0.002           |
| High            | 11.85 (6.61–21.23) | <0.001           | 9.18 (4.15–20.34) | <0.001           | 5.69 (2.93–11.05) | <0.001           |
| Epithelial POSTN score |                   |                   |                   |                   |                   |
| Low             | 1.00             | 1.00             | 1.00             |
| Medium          | 0.63 (0.38–1.04) | 0.069            | 1.06 (0.55–2.04) | 0.868            | 1.22 (0.64–2.32) | 0.541           |
| High            | 0.83 (0.46–1.50) | 0.534            | 1.16 (0.51–2.62) | 0.720            | 3.76 (1.50–9.41) | 0.005           |
| TNM stage (III vs I + II) | 1.86 (1.20–2.88) | 0.006           | 1.53 (0.84–2.80) | 0.167           | 1.39 (0.84–2.32) | 0.204           |
| Differentiation grade (poorly vs well + moderately) | 1.11 (0.75–1.65) | 0.614           | 1.03 (0.55–1.79) | 0.929           | 1.56 (0.68–3.57) | 0.294           |
| Adjuvant chemotherapy (yes vs no) | 1.79 (0.74–4.36) | 0.200           | 1.45 (0.48–4.39) | 0.516           | 1.00 (0.59–1.72) | 0.987           |
| Age (≥50 vs <50 years) | 0.82 (0.54–1.25) | 0.36            | 1.39 (0.72–2.70) | 0.332           | 1.41 (0.79–2.50) | 0.247           |
| Sex (male vs female) | 1.19 (0.81–1.73) | 0.378           | 1.27 (0.74–2.18) | 0.382           | 1.04 (0.63–1.71) | 0.877           |
| Disease location (rectum vs colon) | 1.18 (0.81–1.71) | 0.395           | 1.35 (0.80–2.27) | 0.257           | 1.58 (0.91–2.74) | 0.104           |
| Lymph nodes examined (≥12 vs <12) | 2.22 (1.47–3.33) | <0.001          | 1.96 (1.12–3.45) | 0.019           | 0.94 (0.58–1.55) | 0.819           |
| Serum CEA (ng/ml) (≥5 vs <5) | 0.99 (0.65–1.52) | 0.991           | 1.02 (0.57–1.83) | 0.937           | 1.51 (0.90–2.52) | 0.119           |
| Serum CA19–9 (U/ml) (≥37 vs <37) | 1.52 (0.93–2.51) | 0.098           | 1.42 (0.71–2.82) | 0.324           | 2.02 (1.14–3.58) | 0.015           |

Abbreviations: CRC, colorectal carcinoma; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; IHC, immunohistochemistry.
Figure 3: Effects of stromal POSTN expression in predicting postoperative prognoses of CRC patients with or without postoperative chemotherapy in both cohorts. 

A. DFS of stage I-II CRC patients without chemotherapy in Shanghai cohort. 
B. DFS of stage II CRC patients with postoperative chemotherapy in Shanghai cohort. 
C. DFS of stage III CRC patients with postoperative chemotherapy in Shanghai cohort. 
D. DSS of stage I-II CRC patients without chemotherapy in Shanghai cohort. 
E. DSS of stage II CRC patients with postoperative chemotherapy in Shanghai cohort. 
F. DSS of stage III CRC patients with postoperative chemotherapy in Shanghai cohort. 
G. DSS of stage I-II CRC patients without chemotherapy in Guangzhou cohort. 
H. DSS of stage II CRC patients with postoperative chemotherapy in Guangzhou cohort. 
I. DSS of stage III CRC patients with chemotherapy in Guangzhou cohort. 
Abbreviations and marks: CRC, colorectal carcinoma; DFS, disease-free survival; DSS, disease-specific survival; •, $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. 

www.impactjournals.com/oncotarget
fibroblast cell line, and generated a stable POSTN-expression cell line named CCD-18Co-POSTN. Similarly, the corresponding empty lentiviral vector was applied to generate a control fibroblast clone named CCD-18Co-NC. With the use of quantitative reverse transcription PCR (qRT-PCR) and Western blot, we confirmed that POSTN expression was significantly higher in CCD-18Co-POSTN than in CCD-18Co-NC and parental CCD-18Co cells, respectively (Figure 4A, 4B). To elucidate the effects of POSTN derived from fibroblasts on CRC cells, we examined proliferation, anchorage independent growth, and invasion of SW480 and HT29 cells cultured with conditional media of CCD-18Co-POSTN and CCD-18Co-NC cells, respectively. As expected, SW480 and HT29 cells proliferated faster and formed more clones in CCD-18Co-POSTN medium than in CCD-18Co-NC medium (Figure 4C, 4D, 4E). CCD-18Co-POSTN medium significantly enhanced invasion of SW480 and HT29 cells than did CCD-18Co-NC medium (Figure 4F). To further elucidate the role of POSTN on the aggressiveness of CRC cells and the underlying mechanism, recombinant human POSTN (rhPOSTN), PI3K/Akt kinase inhibitor LY294002, and β-catenin-specific inhibitor XAV939 were applied in the in vitro study of CRC cells. It was found that 100 ng/mL rhPOSTN significantly increased proliferation of SW480 and HT29 cells; whereas 10 μM LY294002 or XAV939 significantly decreased proliferation of CRC cells (Figure 4G). Western blot assays showed that rhPOSTN apparently increased phosphorylation of Akt (pAkt) in SW480 and HT29 cells and expression level of β-catenin in HT29 cells; whereas 10 μM LY294002 or XAV939 apparently reduced rhPOSTN-upregulated expression of pAkt and β-catenin in CRC cells (Figure 4H). Anchorage independent growth of CRC

Figure 4: Effects of POSTN on proliferation, anchorage independent growth, and invasion of CRC cells and its contributing signaling pathways. A. POSTN mRNA levels in CCD-18Co-POSTN, CCD-18Co-NC, and CCD-18Co cells. B. POSTN protein levels in CCD-18Co-POSTN, CCD-18Co-NC, and CCD-18Co cells. C. proliferation of SW480 cells in CCD-18Co-POSTN medium. D. proliferation of HT29 cells in CCD-18Co-POSTN medium. E. anchorage independent growth of CRC cells in CCD-18Co-POSTN medium. F. invasion of CRC cells in CCD-18Co-POSTN medium. G. proliferation of CRC cells treated with 100 ng/mL rhPOSTN, rhPOSTN plus 10 μM PI3K/Akt kinase inhibitor LY294002, and rhPOSTN plus 10 μM β-catenin-specific inhibitor XAV939. H. expression levels of pAkt and β-catenin in CRC cells treated with POSTN and/or signaling inhibitors by Western blot analyses. I. anchorage independent growth of CRC cells treated with POSTN and/or signaling inhibitors. J. invasion of CRC cells treated with POSTN and/or signaling inhibitors. Abbreviations and marks: CRC, colorectal carcinoma; pAkt, phosphorylation of Akt; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
cells was significantly increased by rhPOSTN; however, this effect was significantly counteracted by LY294002 or XAV939 (Figure 4I). Invasion of CRC cells was also significantly increased by rhPOSTN but greatly reduced by the inhibitors, especially by PI3K/Akt kinase inhibitor (Figure 4J).

**POSTN increased the chemo-resistance of CRC cells via activating PI3K/Akt and/or Wnt/β-catenin signaling pathways**

Conditional medium of CCD-18Co-POSTN cells significantly increased the chemo-resistance of SW480 and HT29 cells to 5-fluorouracil (5-FU), compared to counterparts cultured with CCD-18Co-NC medium (Figure 5A). Further experimentation indicated that 100 ng/mL rhPOSTN greatly increased the chemo-resistance of both CRC cells to 5-FU (Figure 5B). Interestingly, the rhPOSTN-increased chemo-resistance of SW480 cells was significantly decreased when the signaling inhibitor LY294002 or XAV939 was present in the culture; the chemo-resistance of HT29 was also decreased by the inhibitors, especially by PI3K/Akt kinase inhibitor LY294002 (Figure 5C).

**Stromal POSTN promoted proliferation, migration, and anchorage independent growth of fibroblasts via paracrine or autocrine modes of action**

To explore the effect of CRC cells on expression of POSTN in colonic fibroblasts, we cultured parental CCD-18Co cells with conditional media of CRC cell lines SW480, HT29, LoVo, and RKO, respectively. It was found that RKO conditional medium significantly induced the expression of POSTN in CCD-18Co, as verified by qRT-PCR and Western blot analyses (Figure 6A, 6B). Surprisingly, CCD-18Co cultured with RKO conditional medium grew significantly faster than did CCD-18Co cultured routinely (Figure 6C).
Figure 6: POSTN promoted proliferation of fibroblasts via autocrine or paracrine modes of action. A. the effect of CRC cell conditional media on POSTN mRNA transcription in CCD-18Co colonic fibroblasts, as measured by qRT-PCR. B. the effect of CRC cell conditional media on POSTN protein production in CCD-18Co cells by western blot analysis. C. proliferation of CCD-18Co cultured with RKO conditional medium and CCD-18Co with normal complete medium. D. proliferation of CCD-18Co-POSTN, CCD-18Co-NC, and parental CCD-18Co cells. E. migration of CCD-18Co-POSTN and CCD-18Co-NC cells in the Transwell chamber without matrigel. F. Invasion of CCD-18Co-POSTN and CCD-18Co-NC cells in the Transwell chamber with matrigel. G. anchorage independent growth of CCD-18Co-POSTN and CCD-18Co-NC cells and the effect of the signaling inhibitor LY294002 or XAV939 on POSTON-upregulated anchorage independent growth and expression levels of pAkt and β-catenin in colonic fibroblasts. Abbreviations and marks: CRC, colorectal carcinoma; pAkt, phosphorylation of Akt; qRT-PCR, real-time quantitative RT-PCR; *, P > 0.05; ***, P < 0.001.
with high POSTN expression also grew faster than did the counterparts with low POSTN expression (CCD-18Co-NC and CCD-18Co) (Figure 6D). Further experimentation indicated that CCD-18Co-POSTN was more migratory but not more invasive than CCD-18Co-NC (Figure 6E, 6F). CCD-18Co-POSTN had a higher clone formation rate than did CCD-18Co-NC, but this effect was counteracted by LY294002 or XAV939. Western blot analyses showed that expression levels of pAkt and β-catenin were higher in CCD-18Co-POSTN than in CCD-18Co cells, however, the levels of pAkt and β-catenin in CCD-18Co-POSTN could be apparently decreased by LY294002 and XAV939, respectively (Figure 6G).

**DISCUSSION**

The present study demonstrated that stromal POSTN expression was gradually increased from normal tissues, primary CRC tissues to metastatic CRC tissues (Figure 1), indicating that stromal POSTN expression accumulates consecutively during CRC progression. Importantly, stromal POSTN expression in primary CRC tissues dose-dependently predicted poor postoperative prognoses and had a higher discriminatory performance than did epithelial POSTN expression. Multivariate Cox regression analyses indicated that medium- and high-score stromal POSTN expression, rather than epithelial POSTN expression, predicted unfavorable postoperative prognoses independently in both cohorts (Table 2). Furthermore, medium-score stromal POSTN expression is comparable to the CRC cell-derived gene signature in predicting DFS of the same CRC patients in Shanghai cohort; while medium- and high-score stromal POSTN expression is also comparable to the CRC cell-derived gene signature in predicting DSS in Guangzhou cohort [8]. Thus, stromal POSTN expression in surgically removed tumors should be a powerful and robust prognostic biomarker for CRC, which is worth being clinically translated.

This study revealed that POSTN secreted from gene-transfected colonic fibroblasts or rhPOSTN greatly promoted proliferation, anchorage independent growth, and invasion of CRC cell lines. These effects of POSTN should be realized via interacting with its receptors, αv-integrins, on CRC cell lines. αvβ3, αvβ5, and/or α6β4 integrin complex are cell surface receptors of POSTN in CRC, pancreatic cancer, epithelial ovarian carcinoma, esophageal adenocarcinoma, and breast cancer cells [10, 21–23]. We found that external POSTN induced phosphorylation of Akt and the expression of β-catenin in CRC cells and the effects of POSTN on CRC cells could be greatly counteracted via targeting PI3K/Akt or Wnt/β-catenin pathway (Figure 4). Based on our findings together with previous publications [9, 10, 14, 17, 18, 21, 22, 24, 25], we believe that POSTN may induce phosphorylation of Akt and focal adhesion kinase (FAK) after binds to its receptors, thus activating PI3K/Akt, NK-κB/STAT3, and ERK pathways, and inducing the expression of multiple downstream genes such as α-smooth muscle actin, fibronectin, chemokines, and transformating growth factor β (TGF-β). POSTN also functions as a driver of EMT and induces expression of matrix metalloproteinase (MMP)-9,-10, and -13, resulting in the degradation of extracellular matrix (ECM), and promoting cancer spread and metastasis [24, 26, 27]. Thus, stromal POSTN whose expression accumulates during CRC progression promotes cancer cell survival, growth, and invasiveness via activating oncogenic pathways such as PI3K/Akt and/or Wnt/β-catenin pathways.

We found that stromal POSTN expression in primary CRC tissues dose-dependently predicted an unfavorable prognosis of stage III CRC patients with postoperative chemotherapy (Figure 3). Interestingly, POSTN in cell culture significantly improved the chemo-resistance of CRC cells but this effect was greatly decreased via targeting to PI3K/Akt or Wnt/β-catenin pathways (Figure 5). Tumor stem cells are naturally chemoresistant. Molecules that confer the chemoresistance usually increase the “stemness” of cancer cells via activating the “stemness”-supportive signaling pathways such as Wnt/β-catenin [28, 29]. Ectopic overexpression of POSTN or recombinant POSTN can induce multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells [30]. Expression of POSTN is significantly higher in CD133+ CRC cells compared to CD133- CRC cells [11]. Wnt/β-catenin signaling pathway often promotes the evolution of the chemo-resistant “stemness” of CRC [28, 29, 31]. Targeting PI3K/Akt or ERK signaling pathway can attenuate the growth of CRC cells or sensitize CRC cell lines to 5-FU [32, 33]. Based on our results and the published data, we hypothesize that POSTN derived from colonic fibroblasts facilitates the evolution of cancer stem cells via activating PI3K/Akt and/or Wnt/β-catenin signaling pathways. Our data support that stromal POSTN expression is predictive for chemo-resistance of CRC. Targeting POSTN/αvβ3–6 integrins/PI3K/Akt and/or Wnt/β-catenin pathways should be therapeutic options for metastatic or chemoresistant CRC.

It is well established that chronic inflammation promotes the development of CRC. Some proinflammatory or immunosuppressive molecules including TGF-β1, 2, and 3, vascular endothelial growth factor (VEGF), interleukin (IL)-3, 4, 6, and 13 can induce the expression of POSTN in a cell-specific context [10]. In this study, we found that conditional medium of RKO could induce POSTN production in fibroblasts, possibly because RKO secretes immunosuppressive factors such as TGF-β1, VEGF, IL-4, IL-6, IL-10, and prostaglandin E2 [34]. These CRC cell-derived factors can induce the expression of POSTN in colonic fibroblasts and autocrine POSTN in turn promoted proliferation, migration, and anchorage independent growth of colonic fibroblasts (Figure 6). Cancer cells can induce fibroblast-mediated accumulation
of stromal POSTN and POSTN derived from cancer stem cells can recruit M2 tumor-associated macrophages and promotes malignant growth [35, 36], indicating that POSTN bridges cancer cells and cancer-supportive stromal cells. Like other cancer biomarkers such as α-fetoprotein, POSTN is actively expressed in a specific temporal and spatial pattern during embryogenesis, silenced after birth, and re-expressed in response to mechanical stress or carcinogenesis [9]. These evidences indicate that stromal POSTN may be re-expressed by proinflammatory factors in chronic tumor-supportive inflammation, and facilitate cancer evolution and development via creating a cancer-supportive niche.

In summary, stromal POSTN expression in primary tumor tissues independently predicted an unfavorable prognosis of CRC patients after the adjustment with covariates including TNM stage and postoperative chemotherapy. Stromal POSTN expression also predicted a poor prognosis of CRC patients with postoperative chemotherapy dose-dependently. Both of POSTN derived from colonic fibroblasts and rhPOSTN significantly promoted proliferation, anchorage independent growth, invasion, and chemo-resistance of CRC cells; however these effects were greatly counteracted via targeting to PI3K/Akt or Wnt/β-catenin pathways. CRC cell line RKO-secreted factors can induce the production of POSTN in colonic fibroblasts and POSTN in turn promoted proliferation, migration, and anchorage independent growth of colonic fibroblasts. Thus, stromal POSTN expression is prognostic and predictive for CRC, which is worth being clinically translated. POSTN may facilitate the evolution and development of CRC via creating a cancer-supportive niche. Targeting POSTN-induced signaling pathways should be therapeutic options for metastatic or chemoresistant CRC.

MATERIALS AND METHODS

Patients

Pathologically proven formalin-fixed paraffin-embedded (FFPE) specimens of 1098 CRC patients were enrolled in this study. Of these, 755 received curative surgery in the 1st Affiliated Hospital of Second Military Medical University (Shanghai, China) between January 2001 and December 2009 and 343 received curative surgery in the Sixth Affiliated Hospital of Sun Yet-Sen University (Guangzhou, China) between January 2000 and January 2006. In addition, we also included FFPE specimens of surgically removed adjacent mucosa from 37 CRC patients. TNM staging was reclassified according to the American Joint Committee on Cancer (AJCC) staging system (seventh edition). Some of them, especially stage III CRC patients received a standard postoperative chemotherapy (FOLFOX regimen). Baseline information of each specimen donor in Shanghai cohort was summarized in Table 1. Follow-up exam of 1025 patients with stage I–III CRC were carried out as previously reported [8]. DFS and DSS were defined as previously described [8]. This study was approved by the institutional review boards of The 1st Affiliated Hospital of Second Military Medical University and The Sixth Affiliated Hospital of Sun Yet-Sen University. Informed consent has been obtained.

IHC

TMAs were developed as previously described [8]. IHC was carried out in Pathology Core Laboratory of the 1st Affiliated Hospital of Second Military Medical University. Rabbit polyclonal antibodies to human POSTN (1:500, ab14041, Abcam, Cambridge, UK) were used for IHC according to protocols provided by the manufacturers. The specificity and intratumoral heterogeneity of this antibody has been verified in our previous study [8]. Scores were independently assessed by the first 4 authors and then verified by two pathologists (YY and YD). Briefly, intensity of immunostaining in stromal cells or epithelial cancer cells in tumor specimens was graded as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong); staining extent was graded as 0 (0%–4%), 1 (5%–24%), 2 (25%–49%), 3 (50%–74%) and 4 (>75%). Values of the intensity and the extent were multiplied as an immunoreactive score. POSTN expression was graded as low (scores, 0–4), medium (scores, 6–8) and high (scores, 9–12). Disagreements among the researchers were resolved by consensus.

Cell culture

Human colonic fibroblast cell line (CCD-18Co) and 4 human CRC cell lines (SW480, HT29, LoVo, and RKO) were purchased from American Type Culture Collection (Manassas, VA). All cell lines were maintained in Dulbecco’s Modified Eagle Medium (GIBCO, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO), 100 U/mL penicillin, and 100 μg/mL streptomycin in a 5% CO₂ humidified atmosphere.

Vector construction, transfection, and generation of POSTN-producing colonic fibroblasts

A full-length of human POSTN cDNA clone (CDS-h13016-2) was purchased from Axybio (Changsha, China), released by Sall and EcoRI digestion, and inserted into pLenO-GTP lentiviral vector (Invabio, Shanghai, China). The resulting pLenO-GTP-POSTN lentiviral construct was verified by direct DNA sequencing. The empty pLenO-GTP lentiviral vector served as a negative control, named pLenO-GTP-NC. The two constructs...
pLenO-GTP-POSTN and pLenO-GTP-NC were transfected into 293T cells to propagate lentiviruses, respectively. CCD-18Co cells were incubated with lentiviruses containing pLenO-GTP-POSTN or pLenO-GTP-NC with 4 mg/ml polybrene (Sigma-Aldrich, St. Louis) for 96 hrs, and then selected in the presence of 3.5 mg/ml puromycin (Sigma-Aldrich) for 7 d. Finally, we selected a CCD-18Co-POSTN cell line with stable POSTN expression and a control CCD-18Co-NC cell line.

**qRT-PCR**

qRT-PCR was firstly applied to measure levels of POSTN mRNA. The primers for the examination of POSTN mRNA were 5’-GCACACTCTGGGCATCGTGGGA-3’ (forward) and 5’-AAATCCCATCACCATCTTCC-3’ (reverse), for GAPDH (an internal control) were 5’-TTGACCACCAATGCTTGGG-3’ (forward) and 5’-CTGCGAGATCCGCTTGG-3’ (reverse). qRT-PCR was performed as we previously described [37].

**Western blot**

Rabbit monoclonal antibody (mAb) to human POSTN (1:1000, ab172615, Abcam, UK), mouse mAb to human Phospho-Akt (Ser473) (587F11) (1:1000, 4051, Cell Signaling Technology, Beverly, MA), rabbit polyclonal antibody (pAb) to human Akt (1:1000, 9372, Cell Signaling Technology), rabbit mAb to human β-catenin (1:1000, 8480, Cell Signaling Technology), rabbit pAb to human GAPDH (1:1000, AP0063, Bioworld Technology) were applied for Western blot analysis. Signal intensity of each band was quantified using Genetools software (version 4.02, Cambridge, UK). Relative expression was calculated as that signal intensity of POSTN divided by signal intensity of GAPDH in each lane as previously described [38].

**Proliferation, invasion, and anchorage independent growth assays of CRC cells**

CCD-18Co-POSTN and CCD-18Co-NC were cultured with FBS-free DMEM for 48 h, respectively. The supernatants were aseptically filtered and mixed with 5% FBS as conditional media. SW480 and HT29 were cultured with 100% conditional media of colonic fibroblasts, complete medium with 100 ng/mL rhPOSTN (10299-H08H, Sino Biological, Beijing, China), or complete medium alone, respectively. PI3K/Akt kinase inhibitor, LY294002 (Selleck, Shanghai, China) was added into cell cultures to assess if the effect of rhPOSTN was mediated by these signaling pathways. The same amount of Dimethyl Sulphoxide, dissolvent of the inhibitors, was also added to cell cultures with or without rhPOSTN. Cell proliferation assay was examined by using cell counting kit-8 (Beyotime, China) according to the manufacturer instruction. Cell invasion assay was performed using 8-mm pore size 24-well tissue culture Transwell plates (Corning, NY) as previously described [39], with the exception that 100 ng/mL rhPOSTN was added into medium in both chambers in the experimental group. Anchorage independent growth potential was evaluated by double-layered soft agarose culture system. Diluted SW480 and HT29 cells were seeded into 6-cm culture dishes (1000 cells/dish) and incubated for 14 to 21 days, respectively. Cell clones in the dishes were fixed with 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet for 10 min. The number of stained clones containing >50 cells was counted as survivors, and clone formation rate was calculated with the formula: the number of survivors/1000 × 100%. All examinations were performed in triplicate.

**Chemo-resistance of CRC cells to 5-FU**

SW480 and HT29 were seeded in 96-well plates (5 × 10^3/100 μL per well) and cultured with conditional medium of CCD-18Co-NC, the medium of CCD-18Co-POSTN, 100 ng/mL rhPOSTN, and 100 ng/mL rhPOSTN plus 10 μM each of the 2 signaling inhibitors, respectively. The cells allowed to grow for 24 h and then treated with 5-FU at various concentrations (0, 5, 10, 25, 50, and 100 μg/mL) for 36 h. Number of viable cells was measured by using cell counting kit-8 assay. Then, inhibition of viable cells was calculated according to the inhibition rate, as previously described [7, 40].

**Effects of CRC-derived factors on the production of POSTN in fibroblasts and autocrine POSTN on the growth, migration, invasion, and anchorage independent growth of fibroblasts**

LoVo, SW480, HT29, and RKO were cultured with serum-free DMEM for 48 h. The supernatants of the cells were sterile filtered and mixed with FBS at the final concentration of 10% to make CRC conditional medium, respectively. The conditional medium of each CRC cell line was applied to culture CCD-18Co cells. After 7 days’ culture, CCD-18Co cells were harvested and subjected to Western blot. The growth of CCD-18Co in response to RKO conditional medium as well as cell proliferation, invasion, and anchorage independent growth assays of CCD-18Co-NC and CCD-18Co-POSTN were examined as described above. Cell migration assay was carried out as the invasion assay except that the bottom of the culture insert was not coated with Matrigel. The two inhibitors targeting
Statistical analysis

Kruskal-Wallis test and Mann-Whitney U test was used to evaluate the immunostaining score of stromal POSTN expression in adjacent mucosa tissues, primary CRC tissues, and metastatic CRC tissues of CRC patients. Kaplan-Meier analysis with log-rank test was used to estimate DFS of CRC patients in Shanghai cohort and DSS of CRC patients in Shanghai and Guangzhou cohorts. Multivariate Cox hazard proportion models were applied to determine contributions of stromal POSTN expression and epithelial POSTN expression to the survivals, adjusted for age, gender, disease location, TNM stage, tumor differentiation grade, lymph nodes examined, serum CEA, serum CA19-9, and adjuvant chemotherapy. All statistical tests were two-sided and done with Statistical Program for Social Sciences (SPSS 16.0 for Windows, SPSS, Chicago, IL). P < 0.05 was considered as statistically significant.

ACKNOWLEDGMENTS AND FUNDING

Authors thank Drs Jianhua Yin and Rui Pu for their technical help in lab and Drs. Hongwei Zhang and Rong Zhang and experts responsible for the maintenance of Cancer Registry and Death Certification Systems of Shanghai for their great help in the follow-up study.

This work was supported by the National Key Basic Research Program (973 program) (2015CB554000 to GC) and the National Natural Science Foundation of China (81402005 to CF; 81372671 to WC, 81172307 to HW; and the National Natural Science Foundation of China Research Program (973 program) (2015CB554000 to GC) for their great help in the follow-up study.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917.
2. Schmoll HJ, Van Cutsem E, Stein A, Valentinii V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23:2479–2516.
3. Inuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 2011; 29:1547–1555.
4. Mao C, Wu XY, Yang ZY, Treepleton DE, Yuan JQ, Yu YY, Tang JL. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep. 2015; 5:8065.
5. Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo HJ, Kim HS, Oh N, Song GA, Park DY. Snaill and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget. 2015; 6:20312–20326.
6. Yothers G, O’Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013; 31:4512–4519.
7. Han Y, Cai H, Ma L, Ding Y, Tan X, Liu Y, Su T, Yu Y, Chang W, Zhang H, Fu C, Cao G. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Eur J Cancer. 2013; 49:3420–3430.
8. Chang W, Gao X, Han Y, Du Y, Liu Q, Wang L, Tan X, Zhang Q, Liu Y, Zhu Y, Yu Y, Fan X, Zhang H, et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 2014; 63:1457–1467.
9. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CT, Kudo A. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014; 71:1279–1288.
10. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004; 5:329–339.
11. Wu G, Wang X, Zhang X. Clinical implications of periostin in the liver metastasis of colorectal cancer. Cancer Biother Radiopharm. 2013; 28:298–302.
12. Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, Fukayama M. Periostin is expressed in pericycral fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem. 2008; 56:753–764.
13. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA, Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology. 2007; 132:1447–1464.
14. Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw-Yuh L, Lackner MR, Fu L, Amler LC, Bais C, et al. Up-regulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin Cancer Res. 2015; 21:2941–2951.

15. Tian Y, Choi CH, Li QK, Rahmatpanah FB, Chen X, Kim SR, Veltri R, Chia D, Zhang Z, Mercola D, Zhang H. Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLoS One. 2015; 10:e0121502.

16. Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemens N, Mellone M, Uzoh C, Primrose JN, Blaydes JP, et al. Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J Pathol. 2015; 235:466–477.

17. Kikutchi Y, Kunita A, Iwata C, Komura D, Nishiyama T, Shimazu K, Takeshita K, Shibahara J, Kii I, Morishita Y, Yashiro M, Hirakawa K, Miyazono K, et al. The niche component periostin is produced by cancer-associated fibroblasts, supporting growth of gastric cancer through ERK activation. Am J Pathol. 2014; 184:859–870.

18. Ishiba T, Nagahara M, Nakagawa T, Sato T, Ishikawa T, Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, Thuwajit C. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010; 9:13.

19. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol. 2009; 34:821–828.

20. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T, Lemoine NR. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007; 26:2082–2094.

21. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002; 62:5358–5364.

22. Lee YJ, Kim IS, Park SA, Kim Y, Lee JE, Noh DY, Kim KT, Ryu SH, Suh PG. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol Ther. 2013; 21:1004–1013.

23. Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, Sun C, Xia G. Periostin mediates TGFβ-β-induced epithelial mesenchymal transition in prostate cancer cells. Cell Physiol Biochem. 2015; 36:799–809.

24. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, Takeuchi S, Koike K, Ono J, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012; 122:2590–2600.

25. Sirriwardena BS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Hatano H, Tilakaratne WM, Miyauchi M, Takata T. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer. 2006; 95:1396–1403.

26. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M, Takata T. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res. 2006; 66:6928–6935.

27. Aguilera O, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, et al. Nuclear DICKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. Oncotarget. 2015; 6:5903–5917.

28. Allen JE, El-Deiry WS. Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin. Oncotarget. 2013; 4:184–191.

29. Wang X, Liu J, Wang Z, Huang Y, Liu W, Zhu X, Cai Y, Fang X, Lin S, Yuan L, Ouyang G. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. PLoS One. 2013; 8:e72962.

30. Ayadi M, Bouygues A, Ourat D, Ferrand N, Chouaib S, Thiery JP, Muchardt C, Sabbah M, Larsen AK. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/β-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors. Oncotarget. 2015; 6:18518–18533.

31. Zheng Z, He X, Xie C, Hua S, Li J, Wang T, Yao M, Vignarajan S, Teng Y, Hejazi L, Liu B, Dong Q. Targeting cytosolic phospholipase A2 α in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation. Oncotarget. 2014; 5:12304–12316.

32. Nagaraju GP, Alese OB, Landry J, Diaz R, El-Rayes BF. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget. 2014; 5:9980–9991.

33. Cui C, Feng H, Shi X, Wang Y, Feng Z, Liu J, Han Z, Fu J, Fu Z, Tong H. Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10. Int Immunopharmacol. 2015; 27:110–121.

34. Bakhtyar N, Wong N, Kapoor A, Cutz JC, Hill B, Ghert M, Tandon D. Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. Eur J Cancer. 2013; 49:3537–3546.
36. Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015; 17:170–182.

37. Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, Xu D, Ma L, Cao G. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer. 2011; 117:4201–4211.

38. Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, Xu D, Yu Y, Ma W, Thompson TC, Cao G. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression. Br J Cancer. 2013; 109:3105–3115.

39. Tan X, He S, Han Y, Yu Y, Xiao J, Xu D, Wang G, Du Y, Chang W, Yin J, Su T, Hou J, Cao G. Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients. Cancer Cell Int. 2013; 13:20.

40. Han Y, Cai H, Ma L, Ding Y, Tan X, Chang W, Guan W, Liu Y, Shen Q, Yu Y, Zhang H, Cao G. Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy. Cancer. 2013; 119:3436–3445.